Research & Development
Collagen Matrix wins US FDA 510(k) market clearance for Bioactive Moldable Bone Graft Matrix
15 April 2019 -

Regenerative medicine company Collagen Matrix Inc stated on Friday that it has passed US FDA 510(k) market clearance for its innovative line of Mineral Collagen Composite Bioactive Moldable Bone Graft Matrix through its Spine business unit.

The company disclosed that the Bioactive Moldable Bone Graft Matrix is a perfect trio of anorganic carbonate apatite bone mineral, 45S5 bioactive glass and highly purified Type I collagen that can be moulded into putty for filling irregular defect sites. The matrix is an osteoconductive, bioactive, porous implant that allows for bony ingrowth across the graft site. OssiMend Bioactive Moldable is slowly resorbed and replaced by new bone tissue during the natural healing process.

In addition, the matrix is available in various sizes including a unique 25cm long, 40cc strip for complex spine fusion surgeries, revealed the company.

Following the US FDA clearance, the company said OssiMend Bioactive Moldable joins its wide range of implantable collagen and mineral based medical devices.

Login
Username:

Password:


Related Headlines